KR20160069919A - Anti-inflammatory agent containing allilum hookeri extract - Google Patents

Abstract

The present invention relates to an anti-inflammatory composition containing an Allium hookeri extract as an active ingredient. The Allium hookeri extract has no cytotoxicity and is capable of effectively inhibiting inflammation by verifying the content of various cytokines associated with inflammation. The anti-inflammatory composition containing the extract as the active ingredient can be applied to anti-inflammatory agents for inhibiting inflammation in diseases which involve inflammation and also to cosmetic compositions having anti-inflammatory effects.

Description

ANTI-INFLAMMATORY AGENT CONTAINING ALLILUM HOOKERI EXTRACT "

The present invention relates to an anti-inflammatory composition comprising a plant extract having an anti-inflammatory effect, more specifically, a triclosan extract as an active ingredient.

Inflammation is a localized immune response that minimizes the damage of a cell or tissue when it is damaged or destroyed by various factors, such as harmful substances or organisms from the outside, and restores the damaged area to the original state. And is a useful defense mechanism to remove the products produced by tissue damage. As a result, pain, swelling, redness, fever, or the like may occur as a result of the defensive mechanism, resulting in malfunction. Various factors causing inflammation include physical factors such as trauma, burn, bronze, radioactivity, chemical factors such as acid, and immunological factors due to antibody reaction. In addition, blood vessel and hormone imbalance .

The inflammation normally functions to neutralize or eliminate the causative factor through in vivo inflammatory reaction and regenerate the upper tissue to restore the normal structure and function. However, when the degree of inflammation is over a certain level or becomes chronic, chronic inflammation And the like. In addition to being able to observe inflammatory responses in almost all diseases of clinical diseases, enzymes related to inflammatory reaction play an important role in carcinogenesis.

Recently, it has been known that the progress of the inflammatory reaction in the body is related to COX (cyclooxygenase) enzyme activity. The COX enzyme is a major enzyme involved in the biosynthesis of prostaglandin in vivo (Smith et al., J. Biol. Chem., 271, 33157 (1996)), and two kinds of isozyme enzymes, COX-1 and COX -2 is known to exist. The COX-1 is constantly present in tissues such as the stomach or kidney and is involved in maintaining normal homeostasis, while the COX-2 is involved in mitogen or cytokines in inflammation or other immune responses. Is a transient and rapidly expressed enzyme in the cell.

Another strong inflammatory mediator, nitric oxide (NO), is produced from L-arginine by NO synthase (NOS), and is produced by a variety of substances, such as UV, external stress, endotoxin or cytokines Lt; / RTI > cells. These inflammatory stimuli increase the expression of inducible NOS (iNOS) in the cells, thereby inducing NO production in the cells and activating the macrophages to cause an inflammatory reaction.

On the other hand, cosmetics used in everyday life are products used for protecting skin and cleansing the shine, but when the cosmetic composition is examined, ingredients different from the purpose of skin protection are used as indispensable substances for product formation. For example, surfactants, preservatives, fragrances, sunscreens, pigments, and other ingredients used to impart other benefits or effects. Ingredients that are essential for the manufacture of cosmetics are generally known to cause skin irritation, rashes, swelling, and various other side effects.

Further, when sebum components, sweat components, and fatty acids, higher alcohols, and proteins in cosmetic components, which are discharged from the body, are decomposed into highly toxic substances by skin-derived bacteria existing on the skin, they may cause skin inflammation It is well known that skin inflammation is caused by ultraviolet rays from the sun.

In this way, the causes of skin adverse effects in cosmetics are always present and various studies have been conducted to solve them. To date, substances that are used for irritation relief and inflammation relief such as erythema and edema include flutenamic acid, ibuprofen, benzydamine, indomethacin, , Steroids such as prednisolone and dexamethasone, and allantoin, azrene, epsilon-aminocaproic acid, hydrocotisone, licorice acid and its derivatives (? -Glycyrrhetinic acid, glycyrrhetinic acid derivative) It is known to be effective for anti-inflammation.

However, the indomethacin generally used as an anti-inflammatory agent is a substance that can not be used in cosmetics. The amount of hydrocotisin is limited. The licorice acid and its derivatives are difficult to stabilize or have poor solubility, It is difficult to achieve a substantial effect. Thus, known anti-inflammatory agents have problems in terms of skin safety and stability in mixing cosmetics, and their use is limited.

Therefore, it is possible to inhibit the production of NO effectively and without any side-effect or cytotoxic effect with a natural-substance-derived substance, so that the anti-inflammatory effect is excellent, and the inflammation can be suppressed without any side effects. The development of materials that can be used in cosmetics is required.

In recent years, in order to meet the needs of consumers, research and development of cosmetics using natural raw materials have been actively conducted.

KR10-1358405B KR10-2014-0018589A KR10-0941133B KR10-0954984A

In order to meet such a demand, the present invention aims to provide a anti-inflammatory composition comprising as an active ingredient a plant extract which is less likely to cause problems related to side effects.

In addition, there is no problem of side effects from natural plants that can be used for food, unlike existing anti-inflammatory substances, and it is not only excellent in safety, but also inhibits the increase of inflammation-related immune cells, i.e., inhibits inflammatory cytokines And a cosmetic composition containing the plant extract as an active ingredient.

In order to achieve the above object, the present invention provides a anti-inflammatory composition comprising a tubular extract as an active ingredient.

The above-mentioned tubular extract is capable of inhibiting the increase of the immune cells associated with inflammatory diseases, that is, the activity of various cytokines related to inflammation, as well as being derived from natural products, Respectively.

Accordingly, the anti-inflammatory composition of the present invention can be provided as an effective ingredient of the cosmetic composition for the purpose of inhibiting the active ingredient of the anti-inflammatory agent or inflammation.

The inventors of the present invention have been studying a component derived from a natural product having an anti-inflammatory effect, and have found that the extract of Trichophyton japonica has an anti-inflammatory effect and specifically, the Trichoderma extract can inhibit the increase of the immune cells associated with inflammatory diseases, It is possible to effectively inhibit cytokine related to inflammation and it is derived from natural materials and the possibility of side effects is low. Therefore, it was confirmed through the above-mentioned results that the water extract of Panax notoginseng has an excellent anti-inflammatory effect and completed the present invention .

Hereinafter, the present invention will be described in more detail.

The present invention relates to a anti-inflammatory composition comprising a tubular extract, preferably a tubular extract, as an active ingredient.

Allilum hookeri is a perennial herbaceous plant native to the Himalayan region of northern Myanmar. It is also called jumyint in Myanmar. It grows in the high mountains of 1,400 m to 4,200 m above sea level, and does not grow well in the shade. It grows well in damp soil such as around wet ditches. The above-mentioned tub is a yellowish-yellow sphere flower bloomed from August to September, the leaves are symmetrical and linear, the center vein is clear, and the roots are coarse and firm. Though the above-mentioned tripe is strong in spicy taste, it has a bitter taste and sweet taste, and it is said to have three flavors, and it is said that the shape and taste of roots is similar to the root roots of ginseng. The above-mentioned triplex contains components such as sulphur compounds, vitamin A, iron, and calcium, and is particularly used for edible and medicinal purposes because of high content of dihydrogen sulfide compounds. It is known that the above-mentioned triplex has anticancer effect, antioxidative effect, or hypertension control ability, but its anti-inflammatory effect is not known at all.

The tubular extract may be prepared by a conventional method for producing plant extracts. For example, the tubular extract may be prepared by extracting an extract solvent with leaves, branches, stems, fruits, roots or pulverized products thereof, And then fractionating the crude extract with a fraction solvent.

The extraction solvent may be at least one selected from the group consisting of water and an organic solvent. The organic solvent may be a polar solvent such as an alcohol having 1 to 5 carbon atoms, a diluted alcohol, ethylacetate or acetone, a nonpolar solvent such as ether, chloroform, benzene, hexane or dichloromethane, or a mixture thereof. The alcohol having 1 to 5 carbon atoms may be methanol, ethanol, propanol, butanol, isopropanol, etc., but is not limited thereto. In addition, the alcohol diluted water may be an alcohol diluted with water at 50% (v / v) to 99.9% (v / v).

The extraction solvent of the tubular extract of the present invention may preferably be at least one selected from the group consisting of water, an alcohol having 1 to 5 carbon atoms, an alcohol-diluted water, and a mixture thereof, more preferably water, Alcohols, and mixtures thereof, and even more preferably, it may be an aqueous solution of ethanol or ethanol. The extraction process may be performed at, for example, 50 ° C to 150 ° C, or 75 ° C to 120 ° C, or 90 ° C to 110 ° C, but is not limited thereto. The extraction time is not particularly limited, but may be 10 minutes to 24 hours, or 30 minutes to 12 hours, or 2 hours to 6 hours.

The tubular extract of the present invention may be one prepared by a conventional method for producing a plant extract, and specifically may be a heat extraction method including a hot water extraction method, a cold extraction extraction method, a warm extraction extraction method, an ultrasonic extraction method, An extractor or a fractionator may be used.

The extract obtained by the solvent is then subjected to fractionation with any one solvent selected from the group consisting of butanol, hexane, methylene chloride, acetone, ethyl acetate, ethyl ether, chloroform, water and mixtures thereof, preferably butanol Can be further carried out. Two or more kinds of solvents may be used for the fractionation, and each solvent extract may be prepared by sequentially using or mixing the solvents according to the polarity of the solvent

The thus-prepared extract or the fraction obtained by performing the fractionation process may be filtered, concentrated or dried to remove the solvent, and may be subjected to both filtration, concentration and drying. Specifically, the filtration can be performed using a filter paper or a vacuum filter, and the concentration can be reduced by using a vacuum concentrator, for example, a rotary evaporator. The drying can be performed by, for example, freeze drying.

According to one embodiment of the present invention, the tubular extract can inhibit the increase of the immune cells associated with inflammation induction, that is, it can effectively inhibit inflammation-related inflammation-related cytokines. .

Therefore, anti-inflammatory compositions containing the above-mentioned triple extract as an active ingredient can be used for suppressing inflammation or for treating, ameliorating or preventing inflammation.

The inflammation may include one or more selected from the group consisting of various dermatitis, allergies, systemic lupus erythematosus, retinitis, gastritis, hepatitis, enteritis, pancreatitis, arthritis and nephritis. Allergic rhinitis, allergic rhinitis, anaphylaxis, allergic rhinitis, asthma, allergic conjunctivitis, allergic dermatitis, atopic dermatitis, contact dermatitis, urticaria, , Food allergies and drug allergies.

Accordingly, the anti-inflammatory composition of the present invention can be applied as a composition for treating or preventing inflammatory diseases or as a food composition for preventing or ameliorating the inflammatory diseases. The food composition may be, for example, a health functional food composition for preventing or ameliorating the inflammatory disease.

The above-mentioned health functional foods are used to control the bio-defense rhythm of the food group or the food composition imparted with added value to function and express the function of the relevant food by physical, biochemical and biotechnological techniques, Means a food which is processed and designed so that the body controlling function of the body is sufficiently expressed to the living body. The health functional food may include food-acceptable food supplementary additives, and may further include suitable carriers, excipients and diluents conventionally used in the production of health functional foods.

The health functional food composition for preventing or ameliorating an inflammatory disease according to the present invention comprises 0.001 to 99.9% by weight or 0.01 to 50% by weight or 0.1 to 30% by weight or 0.1% by weight, To 15% by weight.

The anti-inflammatory composition containing the above-mentioned tubular extract as an active ingredient can be directly applied to animals including humans. The animal is a group of organisms corresponding to plants. It mainly consumes organic matter as nutrients, and differentiates digestive organs, excretory or respiratory organs. Preferably, it is a mammal, more preferably a human.

The triple extract may be used alone in the anti-inflammatory composition, and may further include a pharmacologically acceptable carrier, excipient, diluent or subcomponent. More specifically, when the composition containing the above-mentioned tubular extract is used as a medicine, or used for medicinal or pharmaceutical purposes, the tubular extract may be mixed with a pharmaceutically acceptable carrier or excipient according to a conventional method, It can be used by dilution.

In this case, the content of the tubular extract in the composition may be 0.001 wt% to 99.9 wt%, 0.1 wt% to 99 wt%, or 1 wt% to 50 wt%, but is not limited thereto, The content of the compound may be appropriately adjusted in a desired amount.

Examples of the pharmaceutically acceptable carrier, excipient or diluent include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, propylhydroxybenzoate, talc, magnesium stearate and mineral oil , Dextrin, calcium carbonate, propylene glycol, liquid paraffin, and physiological saline. However, the present invention is not limited thereto, and any conventional carrier, excipient or diluent may be used. In addition, the pharmaceutical composition may further comprise at least one selected from the group consisting of conventional fillers, extenders, binders, disintegrants, anticoagulants, lubricants, wetting agents, pH adjusters, nutrients, vitamins, electrolytes, alginic acid and its salts, , Fragrances, emulsifiers, preservatives, and the like. The components can be added independently or in combination with the active ingredient triple extract.

In addition, the composition of the present invention may further comprise a substance used as a known substance having a known anti-inflammatory effect, for example, a substance used as a COX-2 inhibitor, an NO inhibitor, or an anti-inflammatory agent.

When the composition is used as a medicine, it can be administered orally or parenterally. In one example, it can be administered through various routes including oral, transdermal, subcutaneous, intravenous or muscular.

In addition, the formulations of the compositions may vary depending on the method of use and may be formulated using methods well known in the art to provide rapid, sustained or delayed release of the active ingredient after administration to the mammal . In general, solid dosage forms for oral administration include tablets, pills, soft or hard capsules, pills, powders and granules, which may contain one or more Excipients such as starch, calcium carbonate, sucrose or lactose, gelatin, and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Liquid preparations for oral use include suspensions, solutions, emulsions, and syrups. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, Sweeteners, fragrances, preservatives, and the like.

Forms for parenteral administration include creams, looses, ONITMENTS, PLASTERS, LIQUIDS AND SOULTIONS, AEROSOLS, FRUIDEXTRACTS, (ELIXIR), INFUSIONS, SACHET, PATCH or INJECTIONS.

Furthermore, the compositions of the present invention may be formulated using any suitable method known in the art or using methods disclosed in Remington's Pharmaceutical Science (recent edition), Mack Publishing Company, Easton PA .

The dosage of the composition may be determined in consideration of the administration method, the age, sex, the severity of the patient, the condition of the patient, the degree of absorption of the active ingredient in the body, the inactivity and the drug to be used in combination. Kg body weight to 500 mg / kg body weight, 0.1 mg / kg body weight to 400 mg / kg body weight or 1 mg / kg body weight to 300 mg / kg body weight, And may be administered once or several times in divided doses. The dose is not intended to limit the scope of the invention in any way.

The present invention also provides an anti-inflammatory agent comprising, as an active ingredient, a anti-inflammatory composition comprising the above-described triple extract as an active ingredient or a triple extract.

The triple extract may preferably be a triple aqueous ethanol extract, more preferably a non-polar fraction of triple aqueous ethanol extract.

The anti-inflammatory agent may include the active ingredient alone, and may further include a pharmaceutically acceptable carrier or excipient depending on the formulation, the method of use, and the intended use. When provided as a mixture, the active ingredient may be contained in an amount of 0.1% by weight to 99.9% by weight based on the whole anti-inflammatory agent, but is usually contained in an amount of 0.001% by weight to 50% by weight.

The anti-inflammatory agent is used for the prevention and treatment of various acute inflammatory diseases such as rheumatoid arthritis, lupus, multiple sclerosis such as various chronic inflammatory diseases, septicemia, shock, rejection of organ transplantation, ophthalmic diseases, bronchitis or inflammatory bowel disease It is possible.

Examples of the carrier or the excipient include water, dextrin, calcium carbonate, lactose, propylene glycol, liquid paraffin, physiological saline, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gelatin, calcium phosphate, But are not limited to, calcium silicate, cellulose, methylcellulose, polyvinylpyrrolidone, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. Two or more carriers or excipients may be used.

In addition, when the anti-inflammatory agent is weakly formulated, it may further contain conventional fillers, extenders, binders, disintegrants, surfactants, anti-coagulants, lubricants, wetting agents, fragrances, emulsifiers or preservatives.

In addition, the anti-inflammatory agent of the present invention may further comprise a compound having a known anti-inflammatory activity, or a plant extract, in addition to the active ingredient, and may be included in an amount of 5 to 20 parts by weight based on 100 parts by weight of the active ingredient.

The formulations of anti-inflammatory agents may be in their preferred forms depending on the method of use, and may be formulated employing methods known in the art to provide rapid, sustained or delayed release of the active ingredient, especially after administration to the mammal. Exemplary formulations include, but are not limited to, excipients, granules, lotions, liniments, rimonadense, powders, syrups, ointments, liquids, aerosols, EXTRACTS, elixirs, ointments, Suspensions, premixes, infusions, eye drops, tablets, suppositories, injections, main tablets, capsules, creams, pills, soft or hard gelatin capsules.

The anti-inflammatory agent according to the present invention may be used orally or parenterally and may be used, for example, through the intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intramuscular, epidural and oral routes, , The age, sex, and weight of the recipient, and the severity of the disease. For example, the anti-inflammatory agent of the present invention can be administered once or more at 0.1 mg / kg (body weight) to 100 mg / kg (body weight) per day based on the active ingredient. However, the above-mentioned dosage is only for illustrative purposes and is not limited to the above range.

The present invention also provides a cosmetic composition comprising as an active ingredient an anti-inflammatory composition comprising the above-described tubular extract as an active ingredient or a tubular extract.

Since the tubular extract is derived from a natural substance, it has no problem of side effects, is not cytotoxic, and has excellent anti-inflammatory and anti-irritating activity because it has excellent inflammation inhibitory effect. Therefore, it is possible to prevent inflammation induced by components contained in cosmetics and external It is possible to effectively control the environment-induced inflammation. Therefore, the anti-inflammatory composition or the triple extract containing the above-mentioned triple extract as an active ingredient can be used as an effective ingredient of a cosmetic composition having an inflammation improving and alleviating effect.

The triple extract may preferably be a triple aqueous ethanol extract, more preferably a non-polar fraction of triple aqueous ethanol extract.

The cosmetic composition may be used as a cosmetic composition for basic cosmetics, makeup cosmetics, body cosmetics, hair cosmetics, scalp cosmetics, shaving cosmetics or oral cosmetics.

Examples of the cosmetic cosmetic include a cream, a lotion, a pack, a massage cream, and a milky lotion. Examples of the cosmetic cosmetic include a foundation, a makeup base, a lipstick, an eye shadow, an eyeliner, a mascara, an eyebrow pencil, Examples of the cosmetic material include soap, liquid cleansing agent, bathing agent, sunscreen cream, and sun oil. Examples of the cosmetic for hair include shampoo, rinse, hair treatment, hair mousse, hair liquid, pomade, hair color, hair bleach Examples of the cosmetic composition for scalp include hair tonic or scarf treatment, and examples of the cosmetic composition for shaving include aftershave lotion or shaving cream. Examples of the oral cosmetic composition include Toothpaste or mouth washer.

The cosmetic composition may contain, in addition to the active ingredient, a component incorporated in the cosmetic composition, for example, a moisturizer, an ultraviolet absorber, a vitamin, an animal or plant extract, an extinguishing agent, a whitening agent, a vasodilator, an astringent, Hormones and the like may be further added. In addition, the cosmetic composition may further include a medicament or a mechanism necessary for infiltrating or transferring the active ingredient into the dermal tissue.

The formulation of the cosmetic composition may take any appropriate form depending on the intended use and the properties of the cosmetic composition. Examples of the formulation include an aqueous solution, a solubilization system, an emulsion system, an emulsion system, a gel system, a paste system, an ointment system, A two-layer system or a water-oil-powder three-layer system. Examples of the formulations are merely illustrative, and the formulations and forms of the cosmetic composition of the present invention are not limited by the above examples.

The active ingredient may be contained in an amount of 0.001 to 50% by weight, preferably 0.01 to 20% by weight, based on the total weight of the cosmetic composition, , And the content of the active ingredient contained in the present invention is not limited by the above content.

The tubular extract of the present invention is a plant-derived extract that is a natural product and has no problems with side effects or safety as well as being able to inhibit the increase of the immune cells associated with inflammatory diseases, and to inhibit inflammation-related inflammation-related cytokines cytokine), and it is derived from natural products and the possibility of side effects is not a problem. Therefore, it has been confirmed that the above results can effectively inhibit inflammation. Accordingly, the anti-inflammatory composition comprising the above-mentioned triple extract as an active ingredient is useful as an anti-inflammatory agent for treating or preventing inflammation-related diseases by inhibiting inflammation, a component that is essential for cosmetic preparation, It can be applied to a cosmetic composition having a feature capable of effectively inhibiting inflammation and the like. Therefore, the present invention can be widely used in the medical industry related to the treatment of diseases related to inflammation and in the field of the cosmetic industry related to control of skin inflammation.

FIG. 1 is a graph showing the anti-inflammatory effect of an aqueous solution of triethanolethanol according to an embodiment of the present invention. Specifically, FIG. 1 is a graph showing the effect of the aqueous ethanolic aqueous solution extract according to the treatment amount (horizontal axis, mg / The abscissa of the graph shows the throughput of the aqueous solution extract of ethanol and the throughput of the comparative group. The vertical axis of the graph indicates the number of each immune cell, FIG. 1A shows the results of counting the number of whole immune cells. FIG. 1B shows the results of measurement of the number of white blood cells (WBC). FIG. 1C shows the number of mononuclear leuconocytes FIG. 1d shows the result of measuring the number of neutrophils, FIG. 1e shows the number of eosinophils in the side The results are as follows.
FIG. 2 is a graph showing the anti-inflammatory effect of the aqueous extract of triethanolethanol according to an embodiment of the present invention. FIG. 2 is a graph showing the cytokine content measured in terms of the amount of triethanolamine aqueous solution extract (horizontal axis, mg / (Pg / ml) and TNF-a (pg / ml), which are cytokines that induce inflammation according to the weight of the animal's body weight) (Pg / ml). FIG. 2b shows the results of measurement of the amount of IL-6 (pg / ml), and FIG. 2 -a < / RTI >

Hereinafter, the structure and effects of the present invention will be described in more detail with reference to specific examples and comparative examples in order to facilitate understanding of the present invention. However, it should be understood that the following examples are for the purpose of further illustrating the present invention and are not to be construed as limiting the scope of the invention as defined by the appended claims. All technical ideas are to be construed as falling within the scope of the present invention.

< Example  1> Triptych  Preparation of extract

Allilum hookeri ) extract was prepared by the following method.

Specifically, after buying the triplets cultivated in Jeollanam-do Naju area, the triplets were washed three times in the running water to remove impurities, and then the triplets were air-dried for 3 days at a temperature of 10 ° C to 20 ° C, And pulverized by a pulverizer.

5 kg of a 70% aqueous ethanol solution was added to 1 kg of the above-mentioned triangular shaped pulverized product, and the mixture was extracted at 15 DEG C for 72 hours and then concentrated under reduced pressure using a vacuum evaporator. The concentrated aqueous solution of the triple ethanol aqueous solution was sterilized using a 400 mesh filter cloth as a filter, and then lyophilized at -70 ° C to prepare a powdery crude extract. The crude extract was dissolved in distilled water to prepare a sample of each triplex extract. The sample of the triplex extract was stored at -20 ° C. until use.

Further, the above-mentioned extract of 70% ethanol aqueous solution was concentrated under reduced pressure to remove the ethanol layer. After the solvent was removed and dried, the obtained extract was dissolved in water, and hexane was mixed at a ratio of 1: 1 on the basis of the volume ratio to the extract dissolved in the water solvent, and the hexane layer was separated twice. The hexane layer was separated, and the hexane layer was separated and the remaining water layer was fractionated twice by mixing ethyl acetate, acetone and ethanol at a ratio of 1: 1 on the basis of the volume ratio as described above, and then removing the water layer , And each solvent fraction was prepared. In this fractionation, the ethyl acetate fraction finally yielded 50 g at a yield of 5%.

The extracts and fractions were dried and stored at -20 &lt; 0 &gt; C until use.

< Example  2> Triptych  Identification of the anti-inflammatory effect of the extract

In order to confirm the anti-inflammatory effect of the above-mentioned tubercle extract, it was confirmed using an animal model.

Specifically, in the experimental animals, 54 ICR mice of 4 weeks old male were purchased from Sam Tacio Bio (Korea) and classified into 7 groups. The experimental animals were housed in a polycarbonate breeding box having a constant light-dark cycle of light of 150 Lux to 300 Lux, a temperature of 20 to 26 ° C and a relative humidity of 40% to 60% from 8:00 am to 8:00 pm Five rabbits were kept in each cage, and feed and water were constantly ingested. The feed for the experimental animals was a general pellet-dried feed (Korean Experimental Animals, Korea). The anti-inflammatory effect was confirmed by using the test animal. The animals were stabilized in an animal room for 8 days after purchase and were classified into 7 groups, and the anti-inflammatory effect was confirmed by air pouch model.

Specifically, 5 ml of the air removed from the back of the experimental animals was added to 6 groups of the ICR mice except for the negative control group (Non), and after 3 days, 5 ml of air was added to form a sac under the subcutaneous route . After the cysts were formed, 30, 100, and 300 mg / kg of the extract of 70% ethanol were administered orally to the experimental group, and 5 and 25 mg / kg of the indomethacin was administered orally to the control group. The above-mentioned triple 70% ethanol extract or indomethacin was administered to the inflammation-inducing group (CR), the three experimental groups administered with the tuberous extract, and the comparative group administered with indomethacin. After 24 hours, Carrageenan was administered to the cyst.

After 2 hours had elapsed from the administration of the 1% collagen solution, the extract was orally administered with 70% ethanol extract or indomethacin again and after 18 hours, the exudates formed in the capsule were recovered.

The recovered exudates were counted by Hemavet Multispecies Hematology System (Drew Scientific Inc, Waterbury, Conn., USA) and counted in FIG. 1. Using the antibodies against IL-6 and TNF-a , And IL-6 and TNF-a, which are the inflammatory cytokines, were measured by ELISA and shown in Fig.

According to the results of the experiment, in consideration of the results related to inhibiting the activation of immune cells related to inflammation and inhibiting the secretion of various inflammatory cytokines in association with the anti-inflammatory effect, It has been confirmed that the triple extract of the present invention can be used as an effective ingredient of a cosmetic composition because it can appropriately control the occurrence of inflammation due to the components used in existing cosmetics as well as replace existing inflammation therapeutic agents It is expected to be.

Claims (5)

Allilum hookeri ) extract as an active ingredient. The method according to claim 1,
Wherein the tubular extract is obtained by extracting at least one selected from the group consisting of water, an alcohol having 1 to 5 carbon atoms, and a mixture thereof with an extraction solvent. 3. The method of claim 2,
Wherein the tubular extract is a fraction obtained by fractionating any one of the solvents selected from the group consisting of butanol, hexane, methylene chloride, acetone, ethyl acetate, ethyl ether, chloroform, water and mixtures thereof into a fraction solvent. An anti-inflammatory agent comprising the anti-inflammatory composition of claim 1 as an active ingredient. A cosmetic composition having anti-inflammatory effect comprising the anti-inflammatory composition of claim 1 as an active ingredient.

Images